David Langleben

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5503984/publications.pdf

Version: 2024-02-01

83	15,101	117625	74163
papers	citations	34 h-index	75 g-index

84	84	84	8172
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 921.	2.4	5
2	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 716-721.	0.6	28
3	Pulmonary capillary recruitment and distention in mammalian lungs: species similarities.. European Respiratory Review, 2022, 31, .	7.1	2
4	Decreased bone morphogenetic protein type II receptor and BMP-related signalling moleculesâ€™ expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. Hellenic Journal of Cardiology, 2021, 62, 84-86.	1.0	1
5	Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662.	2.4	18
6	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
7	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
8	Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease. Journal of Rheumatology, 2021, 48, 616-617.	2.0	2
9	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
10	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.6	9
11	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.8	26
12	Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. International Journal of Cardiology, 2020, 306, 181-186.	1.7	3
13	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Canadian Journal of Cardiology, 2020, 36, 977-992.	1.7	29
14	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation, 2020, 10, 1-10.	1.7	4
15	Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells. Canadian Journal of Physiology and Pharmacology, 2020, 98, 834-839.	1.4	4
16	Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	1.7	4
17	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology, 2020, 317, 188-192.	1.7	5
18	Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L361-L368.	2.9	11

#	Article	IF	Citations
19	Pathophysiology of the right ventricle andÂof the pulmonary circulation in pulmonary hypertension: an update. European Respiratory Journal, 2019, 53, 1801900.	6.7	315
20	Pulmonary capillary recruitment in exercise and pulmonary hypertension. European Respiratory Journal, 2018, 51, 1702559.	6.7	1
21	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.	0.6	29
22	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
23	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.6	22
24	Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1136-1144.	6.4	11
25	Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulmonary Circulation, 2017, 7, 588-597.	1.7	3
26	Right ventricular STâ€elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 555-558.	1.7	0
27	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22.	2.9	15
28	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	6.7	113
29	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	10.7	97
30	Pregnancy as a Possible Trigger for Heritable Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 381-383.	1.7	9
31	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2016, 32, 1520-1530.	1.7	50
32	Evaluation of the Microstatâ„¢ sublingual PCO2 monitor in ambulatory patients. Journal of Clinical Monitoring and Computing, 2016, 30, 77-80.	1.6	3
33	Acute Vasodilator Responsiveness and Microvascular Recruitment in Idiopathic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2015, 162, 154-156.	3.9	20
34	Leaflet Area as a Determinant of Tricuspid Regurgitation Severity in Patients With Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	45
35	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313.	6.7	174
36	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347.	0.6	10

#	Article	IF	Citations
37	Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension. Circulation Research, 2015, 117, 645-654.	4.5	120
38	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1345-1354.	5.6	82
39	The Use of Antidepressants and the Risk of Idiopathic Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2014, 30, 1633-1639.	1.7	15
40	Usefulness of Right Ventricular Dysfunction to Predict New-Onset Atrial Fibrillation Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2014, 113, 913-918.	1.6	18
41	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	2.7	59
42	Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sciences, 2014, 118, 191-194.	4.3	18
43	Pulmonary Capillary Hemangiomatosis. Chest, 2014, 145, 197-199.	0.8	16
44	From the Echo Bed to the Pulmonary Vascular Bed. Chest, 2014, 146, 876-878.	0.8	0
45	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	27.0	1,120
46	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	2.8	1,467
47	Step climbing capacity in patients with pulmonary hypertension. Clinical Research in Cardiology, 2013, 102, 51-61.	3.3	13
48	Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2013, 29, 672-677.	1.7	9
49	ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvascular Research, 2013, 85, 46-53.	2.5	23
50	Pulmonary Arterial Hypertension in the Elderly-Clinical Characteristics and Long-Term Survival. Lung, 2012, 190, 645-649.	3.3	22
51	Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2011, 108, 460-464.	1.6	26
52	Metabolic and Clearance Function at the Pulmonary Microvascular Endothelial Surface in Pulmonary Hypertension. , 2011, , 105-115.		1
53	Systemic Sclerosis and Early-Onset Pulmonary Hypertension. Chest, 2010, 138, 238-239.	0.8	0
54	Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells. Microvascular Research, 2010, 80, 349-354.	2.5	42

#	Article	IF	Citations
55	What is the Current State of Stem Cell Research in PAH?. Advances in Pulmonary Hypertension, 2010, 9, 145-145.	0.1	0
56	Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascular Pharmacology, 2009, 50, 45-50.	2.1	22
57	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	2.8	1,919
58	Near-Term Novel Therapies for PAH. Advances in Pulmonary Hypertension, 2009, 8, 17-20.	0.1	0
59	Pulmonary capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism, 2008, 58, 1156-1164.	6.7	40
60	Endothelin and Its Blockade in Pulmonary Arterial Hypertension. , 2008, , 283-303.		0
61	Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2007, 28, 117-125.	2.1	36
62	Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Journal of the American College of Cardiology, 2006, 47, 2049-2056.	2.8	462
63	Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526.	2.7	78
64	Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension. Chest, 2006, 129, 689-695.	0.8	55
65	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
66	Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. Canadian Respiratory Journal, 2005, 12, 303-315.	1.6	5
67	Cardiac Catheterization in Pulmonary Arterial Hypertension: An Updated Guide to Proper Use. Advances in Pulmonary Hypertension, 2005, 4, 15-25.	0.1	14
68	Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Canadian Journal of Cardiology, 2005, 21, 909-14.	1.7	4
69	Sitaxsentan Therapy for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 441-447.	5.6	674
70	Sustained Symptomatic, Functional, and Hemodynamic Benefit With the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients With Pulmonary Arterial Hypertension. Chest, 2004, 126, 1377-1381.	0.8	58
71	Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12.	2.8	1,542
72	STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials. Journal of Cardiovascular Pharmacology, 2004, 44, S80-S84.	1.9	54

#	Article	IF	Citations
73	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. American Heart Journal, 2002, 143, 4A-10A.	2.7	68
74	Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 902-911.	6.7	43
75	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. Annals of Internal Medicine, 2000, 132, 425.	3.9	905
76	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. Circulation, 2000, 102, 2011-2018.	1.6	153
77	Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension. Circulation, 1999, 99, 3266-3271.	1.6	70
78	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Humans. Circulation, 1999, 99, 1593-1599.	1.6	62
79	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. New England Journal of Medicine, 1996, 334, 296-301.	27.0	2,529
80	Short-term Pulmonary Vasodilation With<scp>l</scp>-Arginine in Pulmonary Hypertension. Circulation, 1995, 92, 1539-1545.	1.6	149
81	Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine, 1993, 328, 1732-1739.	27.0	1,698
82	Interspecies Variation in the Cellular Phase of Blood Fibrinolytic Activity. Experimental Biology and Medicine, 1991, 196, 270-272.	2.4	2
83	Familial Pulmonary Capillary Hemangiomatosis Resulting in Primary Pulmonary Hypertension. Annals of Internal Medicine, 1988, 109, 106.	3.9	117